The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.
[button title=”Read Study” link=”https://clinicaltrials.gov/study/NCT04562532″ target=”_blank” align=”” icon=”” icon_position=”” color=”” font_color=”” size=”2″ full_width=”” class=”” download=”” rel=””]